Trial Profile
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Folinic acid (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Antineoplastics; Cyclophosphamide; Daunorubicin; Doxorubicin; Mercaptopurine; Prednisolone; Prednisone; Tioguanine; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Feb 2024 Results assessing osteonecrosis incidence, characteristics, and risk factors in patients 1-30 years with newly diagnosed high-risk B-ALL on COG AALL0232, published in the Leukemia.
- 07 Jun 2022 Results of an analysis assessing impact of dose modification based on various factors using data from two clinical studies: NCT00075725 and NCT00408005 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 02 Apr 2021 Status changed from active, no longer recruiting to completed.